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Abstract Sphingolipids are a diverse class of signaling
molecules implicated in many important aspects of cellular
biology, including growth, differentiation, apoptosis, and
autophagy. Autophagy and apoptosis are fundamental
physiological processes essential for the maintenance of
cellular and tissue homeostasis. There is great interest into
the investigation of sphingolipids and their roles in
regulating these key physiological processes as well as the
manifestation of several disease states. With what is known
to date, the entire scope of sphingolipid signaling is too
broad, and a single review would hardly scratch the sur-
face. Therefore, this review attempts to highlight the sig-
nificance of sphingolipids in determining cell fate (e.g.
apoptosis, autophagy, cell survival) in the context of the
healthy lung, as well as various respiratory diseases in-
cluding acute lung injury, acute respiratory distress syn-
drome, bronchopulmonary dysplasia, asthma, chronic
obstructive pulmonary disease, emphysema, and cystic fi-
brosis. We present an overview of the latest findings related
to sphingolipids and their metabolites, provide a short in-
troduction to autophagy and apoptosis, and then briefly
highlight the regulatory roles of sphingolipid metabolites in
switching between cell survival and cell death. Finally, we
describe functions of sphingolipids in autophagy and
apoptosis in lung homeostasis, especially in the context of
the aforementioned diseases.
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ALI Acute lung injury
AMPK AMP-activated protein kinase
Apaf-1 Apoptotic protease-activating factor-1
ARDS Acute respiratory distress syndrome
aSMase Acid sphingomyelinase
ATG Autophagy related genes
BPD Bronchopulmonary dysplasia
Caspase Cysteine aspartate-specific protease
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane conductance
regulator
CMA Chaperone-mediated autophagy
COPD Chronic obstructive pulmonary disease
DAPK Death-associated protein kinase
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IPF Idiopathic pulmonary fibrosis
JNK1 c-Jun NH2–terminal kinase 1
LASS5 Longevity assurance homolog 5
LC3 Microtubule-associated protein 1 light chain 3
LPS Lipopolysaccharides
MCRM Mitochondrial ceramide-rich macrodomain
MLE Murine lung epithelial
MOMP Mitochondrial outer membrane
permeabilization
mTOR Mammalian target of rapamycin
mTORC1 mTOR complex 1
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PP2A Protein phosphatase 2
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TNF Tumor necrosis factor
TRAIL TNF-related apoptosis-inducing ligand
ULK1 UNC-51-like kinase
UPR Unfolded protein response
VEGF Vascular endothelial growth factor
Introduction
Sphingolipids are a class of lipids that were named after the
mythological Sphinx because of their enigmatic nature.
They were initially thought to serve strictly as structural
components of the membrane bilayer, but have now been
implicated in various cell-signaling pathways including
cell proliferation, differentiation, and programmed cell
death (PCD) [1]. These molecules display amphiphatic
properties in which the hydrophobic end is comprised of a
sphingoid base that is linked to a fatty acid, while the
hydrophilic end varies in structures consisting of hydroxyl
groups, phosphates and sugar residues. Different lengths,
saturations, and hydroxylations of fatty acids, as well as
different head groups result in an immense diversity of the
sphingolipids species [2]. All sphingolipids can be gener-
ated from a derivation of ceramide. For example, as it is
shown in Fig. 1, ceramide can be deacylated by ceramidase
to sphingosine that then can be phosphorylated by a sph-
ingosine kinase isoenzyme (SphK1 or SphK2) to form
sphingosine-1-phosphate (S1P) [3, 4]. Alternatively, sph-
ingosine can be acylated by ceramide synthase to give rise
to ceramide. Both ceramide and sphingosine can act as a
second messenger to promote apoptosis, cellular senes-
cence, and growth arrest [5]. Sphingomyelin synthase
converts ceramide to sphingomyelin, a structural lipid
mainly localized to the outer membrane leaflet, while
sphingomyelin can give rise to ceramide by the action of
sphingomyelinase (SMase) isoenzymes [6]. Ceramide and
S1P have received attention as they appear to play op-
posing roles in a dynamic relationship known as the
‘‘sphingolipid rheostat’’ [1, 7, 8]. At one end of the scale,
ceramide is typically recognized to initiate apoptosis and
growth arrest, whereas S1P, at the other end, promotes cell
proliferation, survival, mobility, and cell-to-cell adhesion
[9–11]. These two sphingolipids have been shown to play a
role in cell fate processes such as apoptosis, and more re-
cently, autophagy. A general overview of sphingolipid
metabolism and their major functions is shown in Fig. 1.
The role of sphingolipids in lung cell fate will be explored
in this review.
Ceramide
Ceramide can be generated through three known pathways.
De novo synthesis of ceramide is characterized by the rate-
limiting step of condensation between serine and palmitoyl-
CoA catalyzed by serine palmitoyltransferase (SPT) [12].
Any of the sphingomyelinase isoenzymes, acid sphin-
gomyelinase (aSMase), neutral sphingomyelinase (nSMase),
and alkaline sphingomyelinase can use sphingomyelin as a
substrate to produce ceramide [13]. Finally, synthesis of
ceramide through a recycling loop from sphingosine and
glycosphingolipids can also occur by the reverse activity of
ceramidase [14].
Ceramide is a well-known critical mediator of various
cell death pathways, including apoptosis and necrosis [15,
16]. Increased ceramide levels have been associated with
apoptotic cell death in both homeostatic systems as well as
pathological settings as a result of cellular insults including
oxidative stress, chemotherapeutic agents, ischemia and
radiation [5, 17–20]. Studies investigating the mechanism
of ceramide-mediated apoptosis have demonstrated that
ceramide can act on both the intrinsic (mitochondrial) and
extrinsic pathways of apoptosis in a context-dependent
manner [21, 22]. Moreover, ceramide is able to induce
apoptosis by recruitment of death receptors to lipid rafts
and assembly of channels in the outer membrane of the
mitochondria promoting the release of cytochrome c, only
to mention a few amongst several investigated pathways
[22–24]. It has more recently been shown that ceramide has
a significant impact on autophagy, influencing cellular fate
under stress conditions such as amino acid deprivation,
mitochondrial damage, and ER stress [25–30].
Sphingosine-1-phosphate
S1P is well recognized to play critical roles in not only cell
proliferation and survival, but also in cell mobility and
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chemotaxis, cell-to-cell adhesion, angiogenesis, intracel-
lular calcium homeostasis, and cytoskeletal organization
[9, 31–33]. Synthesis of S1P can occur by the hydrolysis of
sphingolipids from the plasma membrane into ceramide
and subsequent N-deacetylation of ceramide to form sph-
ingosine that can be phosphorylated by SphK1 or SphK2 [3,
4] to generate S1P. Signaling actions of S1P can be
executed within the intracellular space, as well as the ex-
tracellular space when it acts as a ligand of five G-protein
coupled receptors (S1P1–S1P5) [34, 35]. These receptors
allow S1P to influence signaling processes including an-
giogenesis, heart development, immunity, and cell move-
ment depending on the receptor that is ligated, cell type,
and the cellular context [3]. S1P is currently understood to
promote cell survival by inhibition of enzymes involved in
ceramide synthesis, as well as activation of the nuclear
factor-jB (NF-jB) signaling pathway [36–39]. Further-
more, S1P has also been recently suggested to induce au-
tophagy accordingly with its protective role against
apoptosis [7, 40, 41].
The broad effects of second messengers generated
through metabolism of sphingolipids (ceramide, S1P) on
regulation of cell fate as well as the plasticity of
sphingolipid metabolism suggests a variety of possible
mechanisms for controlling cell fate. Further study will be
required to elucidate the underlying mechanisms regulat-
ing cell survival or death decisions by these family
members.
Determination of cell fate
Apoptosis
PCD is an essential physiological process involved in de-
velopment, aging, and tissue homeostasis which maintains
normal cellular fate in different organisms [42]. Apoptosis
(PCD1) is a widely recognized mode of PCD in which
complex molecular signaling systems trigger an orderly,
energy-dependent enzymatic breakdown of DNA, lipids,
and other macromolecules [43]. Cells undergoing apoptosis
show typical, well-defined morphological changes charac-
terized as rounding of the cell, shrinkage of pseudopods,
decreased cellular volume, chromatin condensation (py-
knosis), nuclear fragmentation (karyorrhexis) along with






























Fig. 1 Overview of sphingolipid metabolism and their major functions. Refer to text for further details. CoA coenzyme A, S1P sphingosine-1-
phosphate, SMase sphingomyelinase, SphK sphingosine kinase, SPT serine palmitoyltransferase
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cytoplasm followed by plasma membrane blebbing, and
ingestion by phagocytes [43, 44].
In contrast to necrosis, apoptosis does not induce in-
flammation since apoptotic cells do not release their cel-
lular contents into the surrounding interstitial tissue and
rather are quickly engulfed by macrophages or adjacent
normal cells [45, 46]. The mechanism of apoptosis is
highly synchronized and is coordinated by an extensively
studied group of cysteine proteases known as cysteine as-
partate-specific proteases (caspases). Caspases are widely
expressed in an inactive proenzyme form (procaspases),
localized in the nucleus, cytoplasm, endoplasmic reticulum
(ER), the mitochondrial intermediate space, and can be
translocated to the plasma membrane [43]. Caspases have
proteolytic activity and are able to cleave proteins at an
internal aspartic acid site, although different caspases have
specificities involving recognition of neighboring amino
acids [47, 48]. According to their order of activation,
caspases are classified into two groups: (1) the initiator
caspases (i.e. caspase-2, -8, -9, and -10), (2) and effector
caspases (i.e. caspase-3, -6, and -7) [49, 50]. Once acti-
vated, caspases can often activate other procaspases, al-
lowing initiation of a protease cascade that leads to an
irreversible commitment towards cell death.
There are at least two major pathways in mammals that
are involved in the initiation of apoptosis, namely the ex-
trinsic pathway and the intrinsic pathway (Fig. 2). Initiator
caspases are activated upon extrinsic or intrinsic stimuli
that lead to the activation of executioner caspases [49, 50].
Extrinsic and intrinsic pathways differ in their induction
and regulation, although there is now evidence that the two
pathways are linked and intersect at different stages where
molecules in one pathway can influence the other [51].
The extrinsic pathway, also commonly referred to as the
death receptor pathway, is initiated through the ligation of
death receptors (Fas, DR4, DR5, TNF-R1) by their specific
ligands (e.g., FasL, APO-2L, TRAIL, and TNF) [52]. In-
teraction of a death ligand to its corresponding receptor
leads to activation of initiator caspase-8. Active caspase-8
can affect the mitochondria via truncated BID (tBID) and
causes mitochondrial initiator caspase (caspase-9) activa-
tion [43, 53]. All of these events culminate to effector
caspase activation (caspase-3, -7, -6) [52], resulting in
cleavage of different substrates like cytokeratins, PARP,
plasma membrane cytoskeletal proteins (alpha fodrin), and
subsequently provokes morphological and biochemical
aspects of apoptosis.
Sphingolipids have been shown to have direct effects on
regulators of the extrinsic pathway of apoptosis (Fig. 2).
For instance, ceramide has been reported to activate protein
kinase Cf (PKCf), which regulates the activation of c-Jun
NH2-terminal kinase 1 (JNK1) and inhibition of protein
kinase B (PKB or Akt) to induce apoptosis [54–57].
Ceramides are also able to directly bind and activate the
lysosomal protease cathepsin D, a direct effector of apop-
tosis [58, 59]. Upon stimulation with tumor necrosis factor
(TNF)-a increased levels of ceramide stimulate cathepsin
D-mediated cleavage of BID to activate the apoptotic
pathway [58, 59]. Sphingosine acts also as a pro-apoptotic
signaling lipid via suppression of the MAPK/ERK signal-
ing pathway [60]. In contrast, S1P is a suppressor of ce-
ramide-mediated activation of JNK1 by activating pro-
survival Akt/mTOR complex 1 (mTORC1), MAPK/ERK,
and NF-jB signaling pathways [33]. Thus, regulators of the
extrinsic pathway of apoptosis are affected in response to
various sphingolipids (Fig. 2).
The intrinsic or mitochondrial pathway can be initiated
following ER stress, exposure to stresses such as cytotoxic
drugs, ultraviolet radiation, and free radicals which cause
DNA damage [61–64]. DNA damage and ER stress acti-
vates pro-apoptotic members of the Bcl-2 family (Bax/
Bak) and induces mitochondrial outer membrane perme-
abilization (MOMP), ultimately leading to caspase-depen-
dent or independent apoptosis [52, 65]. Anti-apoptotic Bcl-
2 proteins (Bcl-2 and Bcl-xL) counteracts pro-apoptotic
proteins and can delay or inhibit apoptosis [66]. Following
MOMP, release of various polypeptides such as cy-
tochrome c from the mitochondrial intermembrane space
promotes caspase activation and apoptosis. Cytochrome
c in the cytosol binds with apaf-1 (apoptotic protease-ac-
tivating factor-1), inducing its oligomerization and thereby
forming a structure termed the apoptosome. Formation of
the death-inducing signaling complex (DISC) and apopto-
some results in activation of initiator caspases 8 and 9,
respectively [7, 67]. Each then activates effector caspase-3,
which ultimately results in hallmark apoptotic morpho-
logical signatures such as loss of cytoplasm, blebbing of
the plasma membrane, and fragmentation of DNA in the
nucleus [67, 68].
Several studies have highlighted the regulatory roles
of sphingolipids on the intrinsic pathway of apoptosis
(Fig. 2). Ceramides promote the intrinsic pathway by
formation of channels in the outer membrane of the
mitochondria to promote the release of cytochrome c re-
sulting in caspase-9 activation [22, 23]. On the other
hand, dihydroceramide has been shown to inhibit ce-
ramide channel formation [69]. In addition, the intrinsic
pathway can also be stimulated by the inhibitory action
of ceramide on mitochondrial complex III to generate
reactive oxygen species (ROS) [70, 71]. The apoptotic
action of ceramide can also be mediated by the re-
cruitment and activation of pro-apoptotic Bax at the
mitochondria through the PP2A-dependent dephosphory-
lation of Bax and formation of mitochondrial ceramide-
rich macrodomains (MCRMs) [72, 73]. Intriguingly, ce-
ramides synthesized in the ER have been shown to
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transport to the mitochondria where they transiently
permeabilize its outer membrane and stimulate the re-
lease of cytochrome c [74]. Such exchange may limit the
need for ceramide synthesis in the mitochondria to reach
ceramide levels required for initiation of the intrinsic
apoptotic pathway [74]. It has been shown that aSMase-
released ceramide is able to bind directly to lysosomal
protease cathepsin D, leading to cathepsin D activation.
The activated cathepsin D subsequently cleaves BH3-
only protein BID and promotes the mitochondrial apop-
totic pathway [58]. Furthermore, while ceramide-medi-
ated activation of pro-apoptotic protein, BAD, promotes
apoptosis, S1P suppresses apoptosis via BAD inactiva-
tion [75–77]. Sphingosine has been shown to down-
regulate expression of anti-apoptotic proteins Bcl-2 and




























































Fig. 2 Schematic representation of key events in the apoptotic
pathway and regulation of apoptosis by sphingolipids. There are two
main apoptotic pathways. A Extrinsic pathway is triggered when cell
death ligands (e.g., FasL, APO-2L, TRAIL, TNF) bind to their
respective death-receptors (e.g., Fas, DR4, DR5, TNF-R1) and ini-
tiates pro-caspase-8 activation by recruiting FADD. Activation of
caspase-8 results in cleavage of effector caspases, such as caspase-3,-
6,-7, which are involved in the core apoptosis pathway. Furthermore,
caspase-8 can truncate BID (tBID), which later induces the intrinsic
pathway. B The intrinsic pathway can be directly initiated by a variety
of stress signals. Stress signals initiate DNA damage and p53
phosphorylation, which leads to the up-regulation of BH3 only
proteins and consequently results in mitochondrial translocation and
oligomerization of BAX/BAK, followed by MOMP. Mitochondrial
damage leads to cytochrome c release into the cytoplasm. Cytosolic
cytochrome c binds to the pro-apoptotic factor Apaf-1 (in the
presence of dATP) to form an apoptosome. Apoptosomes then
activate caspase-9, which later leads to the activation of caspases-3
and-7, and subsequently to nuclear fragmentation and also chromatin
condensation. Sphingolipids have been shown to modulate apoptosis
at multiple steps of the process. Sphingolipids may directly affect
mitochondria, a strategic center in the control of apoptosis. Ceramide
forms channels in mitochondrial outer membranes and promotes the
release of cytochrome c for caspase-9 activation. Ceramide channel
formation has also shown to be inhibited by dihydroceramide.
Furthermore, ceramide generates reactive oxygen species (ROS) via
inhibition of mitochondrial complex III. The apoptotic action of
ceramide could also be mediated by the recruitment and activation of
pro-apoptotic Bax at the mitochondria through the PP2A-dependent
dephosphorylation of Bax and formation of mitochondrial ceramide-
rich macrodomains (MCRMs). aSMase-released ceramide binds
directly to lysosomal protease cathepsin D, leading to cathepsin D
activation, resulting in cleavage of the BH3-only protein BID and
induction of the mitochondrial pathway of apoptosis. Sphingosine has
been shown to downregulate expression of anti-apoptotic proteins,
Bcl-2 and Bcl-xL, to enhance apoptosis. While ceramide-mediated
activation of pro-apoptotic protein, BAD, promotes apoptosis, S1P
suppresses apoptosis via BAD inactivation
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A far less well understood form of PCD, termed pro-
grammed necrosis or necroptosis, has emerged that does
not appear to require caspase activity and is morpho-
logically distinct from apoptosis. Necroptosis is an alter-
native receptor interacting protein (RIP)-mediated form of
cell death, which is dependent on TNF receptor, Fas and
TNF-related apoptosis-inducing ligand (TRAIL) receptor
activation [80–82]. At a biochemical level, while necrop-
tosis displays molecular pathways distinct from those
controlling cell deaths by apoptosis or autophagy and
represent a different morphology, significant cross-talk
between these pathways have been described in different
studies [83–85]. In some cases, molecular pathways of
necroptosis may involve cellular metabolic alterations as-
sociated with mitochondria and the overproduction of ROS
[86, 87] via different macromolecules such as ceramide.
For instance, Ardestani et al. [87] demonstrated that the
mTNF-a isoform is an effective inducer of programmed
necrosis through a caspase independent ceramide-induced
ROS pathway in mouse fibroblast (L929) cells. In another
study with L929 cells, it has been shown that docosahex-
aenoic acid antagonized TNF-a-induced necroptosis
through attenuating ROS generation, ceramide production
and lysosomal dysfunction [88]. However, other studies
using human intestinal epithelial (HT-29) cells and human
monocytic (U937) cells demonstrated that ROS are not
required for necroptosis [89, 90]. These disparate findings
show the limitation of in vitro bioassays for the evaluation
of necroptosis signaling; hence, the exact role of ceramide
and whether or not necroptosis requires ROS or mito-
chondria has yet to be fully determined in vivo.
Autophagy
Autophagy is a tightly regulated catabolic process that
supplies energy during development and in response to
nutrient stress by carrying out lysosomal degradation of
cell contents [91]. Despite its major role as a survival
mechanism, autophagy has previously been classified as
PCD2 based on morphological grounds, termed ‘‘au-
tophagic cell death’’ to describe a form of caspase-inde-
pendent necrosis-like cell death associated with the
accumulation of autophagosomes in cells [92]. The exis-
tence of autophagic cell death as a bona fide death process
is still controversial, and the casual relationship between
autophagy and cell death remains unproven [93, 94].
Nevertheless, many studies have pointed to intimate rela-
tionships between autophagy and cellular death programs,
which are not yet fully understood [95].
The autophagy pathway is evolutionarily conserved
from early eukaryotes to mammals with as many as 38
Autophagy Related Genes (ATG) identified in yeasts and
their human orthologs [96]. Autophagy is divided into three
distinct forms: chaperone-mediated autophagy (CMA),
microautophagy and macroautophagy [97]. A variety of
stress stimuli including long term starvation, exposure to
cytotoxic compounds, or oxidative stress can lead to CMA
activation which selectively degrades cytosolic proteins in
lysosomes [98]. The exact molecular mechanism that
triggers microautophagy remains unknown. However,
guanosine-50-triphosphate (GTP) hydrolysis and calcium
ions are considered as major initiators of this event in yeast
[99]. Macroautophagy (referred to here as autophagy) de-
grades the bulk of damaged cytoplasmic organelles and
proteins. Autophagy includes mitophagy (mitochondrial
autophagy), ribophagy (ribosomal autophagy), pexophagy
(peroxisome autophagy), ER-phagy (endoplasmic reticu-
lum autophagy), aggrephagy (protein aggregate autophagy)
and lipophagy (fat autophagy) [97].
Autophagosomes are the major particles that are formed
and processed during the autophagy pathway. An au-
tophagosome includes a double-membrane vesicle destined
for degradation of proteins and organelles (cargo) which
finally fuse with lysosomes to form autophagolysosomes
[100]. Autophagosome formation requires the expression
of ATG genes which control levels of Atg proteins [101].
Formation of the structures occurs via three main steps: (1)
initiation (induction), (2) elongation, and (3) maturation
(closure), with subsequent fusion with lysosomes to form
the autolysosome or amphisome [97] (Fig. 3).
The mammalian target of rapamycin (mTOR) consti-
tutes a central checkpoint that suppresses autophagy via
restraining the kinase activity of UNC-51-like kinase
(ULK1) [102, 103]. mTORC1 contains the mTOR catalytic
subunit (raptor/GbL/PRAS40/deptor) and phosphorylates
ULK1 in the absence of amino acid and growth factor
signals [104]. ULK1 Ser/Thr protein kinase, Atg13, and
FIP200 (FIP200 is the mammalian homolog of the yeast
Atg17) form the ULK1 complex [105–107] and regulates
autophagy by phosphorylation of Atg13 and FIP200 [108].
Under stresses such as nutrient starvation, mTORC1 is
inhibited by AMP-activated protein kinase (AMPK) re-
sulting in the disassociation of ULK1 and Atg 13. The
ULK1 complex is then phosphorylated by AMPK and then
initiates vesicle nucleation [105].
Beclin-1 is a platform protein and its complex with class
III phosphatidylinositol 3-kinase (PI3K) has a key regulatory
role in nucleation and assembly of the initial phagophore
membrane [109, 110]. Beclin-1 associates with Vps15,
Vps34, and Ambra1 to form a complex that regulates class III
PI3K, which forms phosphatidylinositol-3-phosphate
(PI3P). Furthermore, Beclin-1 complex can also trigger au-
tophagy via JNK1, and death-associated protein kinase
(DAPK) [111]. PI3P is needed for recruitment of other Atg
proteins as well as formation of the X-shape of initial vesicle
nucleation which can be sourced from the outer
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mitochondrial membrane, ER and/or the plasma membrane
[112, 113]. Elongation of the vesicle requires two ubiquitin-
like conjugation systems. The first involves the formation of
the Atg12–Atg5 conjugate, which appears to act as the E3
ligase of microtubule-associated protein 1 light chain 3
(LC3). The second system initiates autophagosome forma-
tion and involves the conjugation of LC3 to the polar head of
phosphatidylethanolamine (PE) by release of Atg8 from
Atg3 [97]. This conjugation leads to the conversion of the
soluble LC3 (LC3-I) to its lipidated form, LC3-II, which is
incorporated into the autophagosome membrane [113, 114].
Atg9 has also been shown to be recruited by the Atg1-Atg13
signaling complex and has an important role in expansion of
















































Fig. 3 A schematic overview of autophagy machinery and its
regulation by sphingolipids. A Autophagy induction and nucleation
of phagophore membranes (pre-autophagosomal structures): in
nutrient rich conditions (insulin, growth factors and amino acids),
the mTORC1 kinase associates with the ULK1 complex to inhibit the
initiation of autophagy. However, under growth factor deprivation or
nutrient starvation, energy sensor AMPK activates the ULK1
complex by directly phosphorylating ULK1 and by suppression of
mTORC1 activity through phosphorylation, and initiates vesicle
nucleation. Phosphorylated and active ULK1 also promotes phos-
phorylation of Atg13 and FIP200, and dissociates from mTORC1.
PI3K-III and VPS34 together with ATG14, AMBRA1, VPS15, and
Beclin-1 form a protein complex (PI3K-III complex) and initiates
phagophore formation. Autophagosome formation and maturation:
Two ubiquitin-like proteins, Atg12 and LC3, are involved in double-
membrane vesicle (autophagosome) formation, elongation, and
closure. Atg12 is conjugated with Atg5 by Atg7 and Atg10, which
then form a complex with Atg16. This complex works with Atg7 and
Atg3 to conjugate LC3-I with the polar head of phos-
phatidylethanolamine (PE) to produce LC3-II, which is specifically
located on autophagosome structures. Autophagosomes are sequen-
tially fused with lysosomes to form autolysosomes. In the
autolysosome, the autophagosomal cargoes are digested by lysosomal
hydrolases and the contents are released for metabolic recycling.
B Sphingolipids have direct effects on different stages of the
autophagy pathway. At the initial step, ceramide may stimulate
autophagy via PI3K-1/Akt activation which suppresses the inhibitory
effects of mTORC1 on autophagy. Acid sphingomyelinase-derived
ceramide also increases autophagy via reducing mTORC1 activity
during amino acid deprivation in a PP2A-dependent manner. C2-
ceramide-induced decrease of mitochondrial membrane potential
upregulates BNIP3 expression which ultimately leads to induction of
autophagy through dissociation of Beclin-1 from Bcl-2, Bcl-xL, and
Mcl-1 in a competitive manner. Similarly, ceramide-mediated
activation of JNK disrupts the inhibitory Beclin-1:Bcl-2 complex
through direct phosphorylation of Bcl-2. Furthermore, ceramide-
mediated activation of transcription factor c-Jun may increase
autophagy activation via upregulation of Beclin-1 and LC3 expres-
sion. Ceramide may also activate calpain which subsequently cleaves
Atg5 to generate a protein fragment that leads to suppression of
autophagy and apoptosis induction. Mitochondrial ceramide has been
shown to mediate mitophagy through the direct interaction between
ceramide and LC3-II
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from LC3-I to LC3-II is regarded as a critical step in au-
tophagosome formation [116] and also represents a hallmark
for detecting autophagy [97, 116]. Following elongation,
expansion, and closure, the autophagosome with cytoplas-
mic material finally fuses with the lysosome forming an
autophagolysosome, and its contents are subsequently di-
gested by lysosomal enzymes [97].
When the autophagosome proceeds to fuse with a
lysosome, its vesicular contents are degraded into macro-
molecules and are recycled back to the cytosol [7, 91, 112].
This process is conserved in all eukaryotic cells and serves
to maintain homeostasis under normal conditions to pre-
vent accumulation of excess/damaged organelles and pro-
teins. However, under conditions of stress such as nutrient
starvation, oxidative stress, pathogen infection or hypoxia,
autophagy serves as an adaptive cell survival response that
could also lead to cell death in situations of defective or
excessive autophagy [103, 112].
The regulation of autophagy or apoptosis and the interplay
between these two pathways is a complex process involving
various key regulators. Among them, sphingolipids have
been shown to have significant roles in different organ sys-
tems [117–121]. For example, ceramide and S1P have both
been demonstrated to induce autophagy by various
mechanisms. Because of the paradoxical roles of autophagy,
ceramide-dependent autophagy could either promote cell
death (by inducing autophagy cell death, or ‘‘switching’’ the
cell from autophagy to apoptosis) [27, 122–124] or under
certain conditions may induce cytoprotective autophagy [25,
125]. Recently, it has been demonstrated that stimulation of
de novo ceramide synthesis results in dissociation of the
complex formed between Beclin-1 and Bcl-2 through
stimulating the phosphorylation of Bcl-2 by JNK1 leading to
autophagy activation [122]. Likewise, inhibition of ceramide
synthesis resulted in suppression of autophagy [122]. Cer-
amide has been reported to suppress the Akt signaling
pathway resulting in autophagy activation via negative
regulation of mTOR signaling [126], suggesting an upstream
regulatory target of the autophagy pathway. Furthermore,
ceramide-induced autophagy, either by targeting the mito-
chondria or by upregulation of Beclin-1, has been reported to
be linked to autophagic cell death [27, 126, 127]. The role of
ceramide-induced autophagy in the context of the ‘sphin-
golipid rheostat’ has yet to be fully understood and further
investigation is required to determine the mechanisms in-
volved in determination of cell fate when autophagy is
activated.
S1P-induced autophagy may be associated with cell
survival [41], consistent with the well-established ‘sphin-
golipid rheostat’. Lavieu et al. [41] reported that SphK1
(S1P)-induced autophagy protects the cell during nutrient
starvation and cell death. Other sphingolipids such as
gangliosides have been reported to induce the formation of
autophagic vacuoles followed by cell death that is inhibited
by either knockdown of autophagy genes or by an inhibitor
of autophagy [128]. Thus, gangliosides appear to have a
similar role in autophagic cell death as ceramides. It has
been hypothesized that the structural properties of sphin-
golipids may mediate autophagosome formation and
maturation [129]. In support of this hypothesis, inhibition
of sphingolipid synthesis in Saccharomyces cerevisiae re-
duced autophagic activity, but had no effect on Atg12–
Atg5 or Atg8-PE conjugation, or pre-autophagosomal
structure formation [130]. This suggests that sphingolipids
play a critical role in the formation of the autophagosome.
Also, ceramides have been found in the membrane of the
autophagosome, in line with the idea of a structural role of
sphingolipids in autophagy [131]. This review will further
discuss sphingolipid signaling and the consequences of
their induced pathways on cell fate and the delicate balance
between a healthy and disease state lung.
Sphingolipids in the lung
Significance of sphingolipids in lung development
It is widely understood that sphingolipids play key roles in
regulating cellular homeostasis. However, their role in the
regulation of lung development has been of particular in-
terest and has received more attention. Ceramide, S1P, and
their dynamic relationship have been of particular interest.
The de novo pathway of ceramide synthesis has been
linked to apoptotic endothelial cell death and decreased
pulmonary barrier function [19, 132]. In a study conducted
by Medler et al. [132], it was found that de novo ceramide
synthesis resulted in apoptotic cell death in lung endothe-
lial cells by both paracellular and TNF-a-stimulated in-
tracellular ceramide signaling. Increased ceramide
synthesis has also been linked to the development of em-
physema-like disease states in the murine lung, suggesting
that the balance between a pro-apoptotic molecule and a
pro-survival factor, such as S1P, is essential in maintaining
homeostasis in the vasculature of the lung [133]. Further-
more, investigation by Petrache et al. into ceramide-in-
duced effects in the lung have revealed that an excess of
ceramide-induced oxidative stress triggered apoptotic cell
death which led to alveolar enlargement [134]. Superoxide
dismutase has been shown to play a protective role against
apoptosis and alveolar enlargement induced by dispropor-
tionate ceramide, suggesting that there are protective
mechanisms that can be activated to protect or prevent
unwarranted cell death in the healthy lung [134].
It is important to emphasize however, that a regulated
level of ceramide may be necessary for maintenance of
homeostasis in the lung. It is evident now that the
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preservation of the sphingolipid rheostat is important in the
formation of lung structures at all stages of lung development
and physiology [119]. A study showed that pigs exposed to
fumonisin (FB1) (inhibitor of ceramide synthase) resulted in
elevated levels of sphingolipids including sphinganine and
sphingosine, which resulted in alveolar endothelial cell
damage and fatal pulmonary edema [135]. Chronic exposure
to FB1 in rats not only induced renal tumors, but also resulted
in metastatic invasion of the lungs [136]. These findings
suggest that ceramide synthesis is required for an underlying
level of apoptotic cell death in the lungs as an anti-tumori-
genic factor [136]. Xu et al. demonstrated that in murine lung
epithelia the de novo ceramide synthesis pathway is the
major contributing pathway for ceramide production [137].
Longevity assurance homolog 5 (LASS5) was found to be
the predominant ceramide synthase in murine primary type II
epithelial cells and SV40-transformed murine lung epithelial
(MLE) cells. Indeed, inhibition of ceramide synthase activity
by FB1 was shown to inhibit the production of ceramide
[137]. Furthermore, this study also showed that overex-
pression of LASS5 reduced phosphatidylcholine (PtdCho)
production, suggesting that ceramide may regulate PtdCho
metabolism in pulmonary cells [137].
In-depth investigation into the levels of sphingolipids in
a developing rat lung revealed that maintenance of sphin-
golipid levels and their metabolism are highly regulated. In
the embryonic rat lung, sphingomyelin and sphingosine
levels increase during development and plateau at birth.
Interestingly, the activity profiles of SPT, aSMase and
nSMase correlate accordingly [138]. In contrast to the rat
lung, sphingomyelin levels in the fetal lung of the monkey
and lamb decrease during development [139, 140]. These
findings suggest that regulation of sphingolipid metabolism
is important in proper lung development and any imbal-
ances or misregulations in the sphingolipid rheostat could
lead to improper lung structure or disease states (Table 1).
Sphingolipids in pulmonary disease
Acute lung injury/ARDS
Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are conditions that are characterized by
lung inflammation, increased microvascular permeability,
and edema [119, 141]. The contributing role of sphin-
golipids in attenuating injury to the lung during ALI and
ARDS has been recently explored and is now well estab-
lished that there are a number of mechanisms including the
neutral sphingomyelinase (nSMase), ceramide, S1P, and
the p38 MAPK pathway, that appear to be involved in the
pathological process [2, 142].
The influence that sphingolipids have on neutrophil cell
fate in an ALI/ARDS disease state is of particular interest
as it is well established that the longevity of neutrophils
correlates with the severity of the pathological state [143,
144]. Under homeostatic conditions, neutrophils will un-
dergo unprompted apoptosis [145]. However, neutrophils
that are recruited to occupy the alveolar space during lung
injury contribute to the pathogenesis of ALI and ARDS by
production and secretion of proteases and ROS for the
duration of their survival [146]. Thus, neutrophil apoptosis
is essential for resolution of inflammation, especially in the
context of an injury to the lung.
It has been reported that apoptosis of neutrophils from
patients with sepsis was suppressed via a mechanism in-
volving NF-jB, reduced caspase-9 and caspase-3 activity,
and maintenance of mitochondrial membrane potential
[147]. Another study found that sphingolactone-24 (Sph-
24) (nSMase inhibitor) and SKI-II (sphingosine kinase in-
hibitor) prevented the anti-apoptotic effect of lipopoly
saccharides (LPS) on neutrophils, and that LPS stimulates
sphingomyelinase activity suggesting that sphingolipids are
involved in inhibition of neutrophil apoptosis [142]. When
Sph-24 was administered to LPS challenged lungs in mice,
counts of leukocytes decreased after a period of 24 h
suggesting that nSMase accelerates injury progression
during lung injury by deceleration of neutrophil apoptosis
[142]. They also demonstrated that LPS challenge of
neutrophils that have been recruited to the lung also display
an increase in S1P levels. This study also revealed that the
increased levels of anti-apoptotic S1P are likely the result
of activation of the nSMase-S1P pathway [142]. S1P is
generated by SphKs that are stimulated by factors such as
histamines and cytokines which could explain the increase
of SphK activity in the injured lung [142, 148]. Thus, both
nSMase and S1P play key roles in the pathogenic process
of ALI/ARDS, particularly in their influence of preventing
neutrophil apoptosis. In ALI, increased nSMase activity
augments ceramide and subsequent sphingosine formation
that then is phosphorylated to S1P by activated sphingosine
kinase, leading to phosphorylation of p38 MAPK resulting
in inhibition of neutrophil apoptosis [142, 149]. Greater
understanding in the pathogenesis of ALI/ARDS and the
role sphingolipids play in cell fate will improve detection
and treatment of this critical condition.
Bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) is amongst the most
common chronic lung diseases of neonates affecting be-
tween 52 and 7 % of infants born weighing between 500
and 1500 g, respectively [150]. Very premature infants that
are subjected to mechanical ventilation and oxygen sup-
plementation due to respiratory failure are prone to lung
injury that may result in chronic lung disease, such as BPD,
with lifelong consequences [151]. The lungs of present day
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BPD patients are characterized by a halt in lung develop-
ment, with simplification of normal lung complexity as
seen with fewer and larger alveoli and vascular abnor-
malities [152]. It was recently demonstrated that changes in
sphingolipid levels may affect proper lung development
and function when Tibboel et al. elegantly demonstrated
that newborn mice that were exposed to hyperoxic condi-
tions displayed an increase in multiple sphingolipids, in-
cluding ceramide [118]. This caused abnormal alveolar
morphology and obstructive lung function that were only
partially recovered in room air [118]. The use of D-sph-
ingosine reduced ceramide levels and partially minimized
halt in alveolarization, demonstrating that altered sphin-
golipid levels may be a factor in hyperoxia-induced lung
injury or BPD [118]. Recently, it was shown that levels of
vascular endothelial growth factor (VEGF), a critical factor
in pulmonary vascular development, were decreased in a
rodent animal model of BPD [153], thereby most likely
reducing alveolarization [154, 155]. Increased ceramide
production has also been shown to decrease VEGF by
suppression of hypoxia-inducible factor-1a [156]. These
findings suggest that sphingolipids play a role in abnormal
lung vascular development through VEGF signaling in
BPD. In another study, apoptosis was detected in alveolar
epithelial cells in the lungs of preterm infants that were
subjected to ventilation and oxygen treatment [157].
Similar results have been reported in mouse models of
BPD [158]. Kroon et al. observed that mechanical venti-
lation of newborn rat resulted in increased number of
apoptotic alveolar type II cells [21]. Prolonged maximal
cyclic stretch was also associated with increased expres-
sion of cleaved caspase-3, -7, and -8, as well as apoptotic
mediator Fas ligand (FasL), suggesting that the extrinsic
death pathway via the FasL/Fas system is involved in
ventilation-induced apoptosis of alveolar type II cells
[21].Given these findings, it is worthwhile to investigate
the role of ventilation-induced ceramide production in
epithelial cell apoptosis as a mechanism responsible for
pulmonary apoptosis and inhibition of alveolar develop-
ment in preterm infants with BPD. The possibility that
altered levels of various sphingolipids can change cell fate
during mechanical ventilation opens potential areas of
therapeutic interventions for BPD to reduce lung damage in
premature infants that require respiratory assistance.
Table 1 Effects of sphingolipids in pulmonary diseases
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Asthma
Asthma is a complex chronic inflammatory lung disease
that is characterized by airway wall remodeling, airway
smooth muscle contraction and hyperreactivity, increased
mucus production, and inflammatory cell gathering [159].
It has increasingly become apparent that sphingolipid
metabolites play a regulatory role in the pathogenesis of
asthma [160]. S1P is often attributed to act as a pro-sur-
vival signal in cells [9], and increased levels in the asth-
matic airway appear to play a role in perpetuating the
asthmatic response [161]. The role of S1P in the patho-
genesis of asthma is well illustrated by the fact that S1P is
involved in trafficking and chemotaxis of immune cells,
such as mast cells, to the airway. Interestingly, S1P release
from the immune cell and binding (in autocrine and para-
crine signaling) with S1P1 receptors in low antigen con-
centrations facilitates mast cell chemotaxis, while
activation of S1P2 receptors in high antigen concentrations
ceases chemotaxis and initiates degranulation [162]. S1P
not only plays an important role in immune cell movement,
but also appears to act as a mitogenic factor and a
stimulator of proliferation of the airway smooth muscle
cells. S1P increases G1/S progression in the cell cycle
which results in augmented EGF- and thrombin-induced
DNA proliferation [161, 163]. SphK has been shown to
play important roles in other inflammatory and hyper
proliferative diseases, and has received attention with the
prospect of developing specific SphK inhibitors for
therapeutic and treatment purposes [164].
Research efforts have recently been focused on the
possibility that genetic predisposition of the asthmatic
respiratory tract significantly affects the severe reaction to
allergic and/or inflammatory stimuli with strong evidence
that genetic variation at the 17q21 locus is linked with
childhood asthma [165]. The locus gene orosomucoid
1-like 3 (ORMDL3) that belongs to a gene family encoding
ER transmembrane proteins has been recently identified to
be related to the pathogenesis of asthma [166, 167]. Sys-
tematic evaluation of single nucleotide polymorphisms
(SNPs) and patients with childhood onset asthma have
revealed that genetic variants regulating ORMDL3 ex-
pression may alter susceptibility to asthma [167].Oroso-
mucoid-like (ORMDL) proteins act as negative regulators
of SPT that are mediated by a feedback response, thus
increased levels of the ORMDL proteins result in a de-
crease in ceramide and higher order sphingolipid biosyn-
thesis as a result of inhibited de novo sphingolipid
synthesis [168, 169]. Expression of the ORMDL3 gene is
increased in asthmatic airways, which results in decreased
de novo ceramide synthesis and also has been associated
with airway hyperreactivity in mouse lungs, and human
and murine bronchial rings [159]. Worgall et al. [159]
investigated the effect of decreased SPT activity in the lung
by pharmacologic intervention with myriocin (SPT in-
hibitor) as well as in SPT heterozygous knockout mice and
observed increased bronchial reactivity in the absence of
inflammation. They also found that intracellular magne-
sium homeostasis and bronchial sensitivity to magnesium
was affected by decreased SPT activity, providing a
mechanistic link between decreased de novo sphingolipid
synthesis, altered contractile sensitivity to magnesium, and
smooth muscle function in asthma [159]. This emerging
evidence that ORMDL proteins affect sphingolipid meta-
bolism in asthmatic airways suggests that it is highly likely
that a genetic predisposition to altered sphingolipid meta-
bolism plays a significant role in the pathogenesis of
asthma.
COPD and emphysema
Chronic obstructive pulmonary disease (COPD) encom-
passes a spectrum of pathological conditions, including
emphysema, that are characterized by difficulties breathing
due to obstructed airflow [170]. Emphysema is found al-
most exclusively in adults and is often associated with
inhalation of cigarette smoke but can also result from ex-
posure to environmental pollutants, typically worsening
over time [171]. Patients with emphysema particularly
have a loss of alveolar surface area available for gas ex-
change due to destruction of distal airway spaces [171].
The mechanisms involved in the pathogenesis of COPD
include inflammatory responses in the airway, loss of
barrier function, oxidative, and ER stress responses. In
addition, both apoptosis and autophagy of the cells in the
airways are generally accepted to be important events in
the pathogenesis of COPD and pulmonary emphysema
[172]. However, it is very important to note that in most
studies the smoking status of the control population was
unknown or was significantly different from that of the
COPD subjects [173–176]; thus, it is not fully understood
whether the habit of smoking has a role in inducing
apoptosis independently of airflow limitation.
It is now recognized that sphingolipids play important
roles in the development of COPD with no surprise that
ceramide appears to be a crucial mediator in the apoptotic
death of alveolar cells [19, 177]. For instance, in rat and
mice emphysema models, inhibition of de novo synthesis
of ceramide induced by VEGF blockade prevented alveolar
cell apoptosis and oxidative stress [19]. Moreover, when
ceramide was introduced through intratracheal instillation
of mice, apoptosis of lung alveolar cells and total ceramide
levels increased [19]. More importantly, lung ceramide
levels are markedly higher in individuals with emphysema
from chronic cigarette smoking compared to individuals
without emphysema [19]. In this study, the authors
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conclude that de novo ceramide synthesis is essential for
the development of murine lung emphysema [19]. At the
molecular level, activation of nSMase2 during cigarette
smoke-induced oxidative stress of human airway epithelial
(A549) cells has been shown to generate ceramide and
apoptosis [178]. Both proto-oncogene tyrosine-protein ki-
nase Src and p38 MAPK appear to be involved in
regulating nSMase2 phosphorylation and activation [179].
Despite higher expression of ceramide in the lungs of
COPD and idiopathic pulmonary fibrosis (IPF) patients, this
phenomenon does not appear to be specific and related to
COPD severity [180]. Scarpa and colleagues [180] studied
10 subjects with severe COPD, 13 with mild/moderate
COPD, 11 with IPF, 12 non-COPD smokers, and 11 non-
smoking controls. They found an increase in ceramide
levels in COPD patients compared to control smokers,
which correlated to the impairment of gas exchange but not
to the degree of airflow limitation. A recent study conducted
by Tibboel et al. revealed that the addition of a SPT in-
hibitor to a rodent model of elastase-induced emphysema
diminished the increase in ceramides and improved lung
function [177] suggesting that ceramide upregulation in
emphysema models may be a critical factor in the devel-
opment of alveolar destruction in the disease state, and
serves as a potential therapeutic target that warrants further
investigation.
The functional significance of autophagy in disease
states such as COPD has yet to be established since
relatively few studies have been done on the lung. Few
in vivo and in vitro specimens of COPD lung exhibit in-
creased levels of autophagy markers when exposed to ci-
garette smoke or cigarette smoke extract, possibly as a
response to a source of stress on the lung [73, 128, 181],
and there have been reports suggesting that the autophagic
process plays an important role in the pathogenesis of
COPD perhaps via promoting epithelial cell death [181–
183]. Recently, Fujii et al. found autophagy impairment in
COPD [184]. Despite high baseline levels of autophagy in
primary human bronchial epithelial cells isolated from
COPD patients, cigarette smoke extract significantly re-
duced autophagy [184]. Furthermore, higher levels of p62
and ubiquitinated proteins have been detected in lung ho-
mogenates from COPD patients suggesting that insufficient
autophagic clearance of damaged proteins may be involved
in cell senescence in COPD patients [184]. As mentioned
earlier, increased expression of ceramide has been detected
in emphysema and may play a critical role in impaired
autophagy in the context of COPD. However, the role of
ceramide in smoke-induced COPD is not yet well studied
and it may be worthwhile to investigate whether the in-
crease of ceramide content in lungs when exposed to ci-
garette smoke also has an impact on autophagy, and if the
pathway plays a pathogenic role in COPD.
Cystic fibrosis
Cystic fibrosis(CF) is caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR)
gene that codes for a chloride channel that mediates proper
movement of chloride ions in epithelial cells [185, 186].
The disease has a median predicted age of survival of
49.7 years [187] and is characterized by accumulation of
mucus in the bronchi, and reduced mucociliary clearance
ultimately leading to recurrent and/or chronic infections
with bacteria including S. aureus and P. aeruginosa [162].
Ceramide has been measured at higher concentrations in
CF airways and appears to be an important factor in the
hallmark features of CF and cellular fate in the affected
lungs [6]. Several studies have shown that CFTR dys-
function leads to an imbalance in sphingolipid homeostasis
[6] and that its localization in the lipid raft influences
membrane ceramide composition [188, 189]. Furthermore,
results of studies using Cftr-/- mice and human lung tissue
demonstrate that CFTR expression inversely correlates
with ceramide accumulation and severity of emphysema in
COPD subjects, demonstrating a critical role of membrane-
localized CFTR in ceramide regulation and inflammation
in lung injury and emphysema [188, 189]. Ceramide ap-
pears to be a critical regulator of P. aeruginosa infection in
CFTR-deficient mice [6]. CFTR-deficiency results in al-
kalinization of acidic prelysosomes and lysosome vesicles
which likely alter the balance of enzymes that increase and
decrease levels of ceramide in the cells, which ultimately
results in an increase of ceramide concentration in the lung
epithelial cells of CFTR-deficient mice [6]. Accumulation
of ceramide in the cells led to apoptosis and DNA depo-
sition in the upper airways that facilitated P. aeruginosa
infection. Treatment of CFTR-deficient mice with
amitriptyline (aSMase inhibitor) normalized ceramide
levels and prevented pulmonary infection with P. aerugi-
nosa [6]. CFTR-deficient mice also display an upregulation
and activation of CD95 (Fas/APO-I receptor) caused by
increased ceramide concentrations, further propelling in a
feedback cycle [185]. CD95 is also involved in an increase
of bronchial cell death, identifying a potential relationship
between CD95 and ceramide as an important mechanistic
link in CF [185]. It has yet to be fully understood if these
findings can be transferred into a human system, however
results thus far have suggested that disruption of ceramide
formation may serve as a prospective treatment for patients
with CF.
Closing remarks
Sphingolipids play an important role in many physiological
and pathological processes across many organ systems and
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diseases. The vast number of sphingolipids is reflected in
the spectrum of signaling mechanisms they are involved in.
Different sphingolipids have key roles in determining cell
fate in many cells throughout nearly all organ systems.
Ceramide is known to induce apoptosis in cells while S1P
counterbalances ceramide and promotes cell survival in
what is referred to as the sphingolipid ‘rheostat’. These
effects are of significance in the lungs and its diseases such
as ALI/ARDS, BPD, asthma, COPD, emphysema, and CF.
Investigation into the lung, its diseases, and the effects of
sphingolipids on cell fate using animal and human models
have provided great insight into the pathogenesis of the
disease states as well as potential interventions that can be
used to improve outcomes for patients. In this regard, in-
hibitors of the sphingolipid pathway show great therapeutic
potential and should be investigated and functionally
validated for their protective effects and benefit for the
patients. This certainly broadens the options of treatment
and care for those suffering from devastating lung diseases
for which treatments are limited.
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